Skip to main content
Mijn bibliotheek
Shop
Nieuws
Boeken
Tijdschriften
E-learning
Web-tv
Video
Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Quality of Life Research

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in: Quality of Life Research 5/2015

01-05-2015

Insomnia, hypnotic use, and health-related quality of life in a nationally representative sample

Auteurs: Julieta Scalo, Pooja Desai, Karen Rascati

Gepubliceerd in: Quality of Life Research | Uitgave 5/2015

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

To assess health-related quality of life (HRQoL) associated with insomnia and prescription hypnotic use.

Methods

Primary outcomes were mental component summary (MCS) and physical component summary (PCS) scores from the 12-item Short-Form Health Survey. Using multiple regression, subjects in the 2005 through 2009 Medical Expenditure Panel Survey with diagnosed insomnia were compared against those without that diagnosis. Among subjects with diagnosed insomnia, users of prescription hypnotics were compared against nonusers.

Results

Of 104,274 adults, 1.3 % (n = 1,401) had an insomnia diagnosis. Of those, 45.6 % (n = 639) used prescription hypnotics. For subjects with insomnia, mean PCS and MCS scores were 9.2 and 7.0 points lower (p < 0.001), respectively. After controlling for demographic and clinical covariates, differences remained significant (PCS:5.1; MCS:6.2; p < 0.001). Among subjects with insomnia, HRQoL scores were not different between prescription hypnotic users (n = 639) and nonusers (n = 762). Analysis by drug class revealed lower PCS scores (difference: 7.5, p < 0.001) with benzodiazepine use (n = 129) versus benzodiazepine receptor agonist use (n = 493), but the adjusted difference was not significant (difference: 3.8, p = .018).

Conclusions

Diagnosed insomnia was associated with consistent decreases in both physical and mental HRQoL scores, regardless of whether prescription hypnotics were used. Benzodiazepine use may be associated with a further decrease in physical HRQoL scores. Although limited by its retrospective design, this study provides a first look at real-world hypnotic use outcomes at a national level. Important next steps include studies with patients serving as their own controls, and further evaluation of the sensitivity of HRQoL instruments to the effects of insomnia treatments.
vorige artikel Predicting participation in meaningful activity for older adults with cancer
volgende artikel Health-related quality of life in women referred for bone density assessment: relationships with bone mineral density, fracture and co-morbidity
Literatuur
1.
Léger, D., & Poursain, B. (2005). An international survey of insomnia: Under-recognition and under-treatment of a polysymptomatic condition. Current Medical Research and Opinion, 21, 1785–1792. CrossRefPubMed
2.
Morin, C. M., LeBlanc, M., Daley, M., Gregoire, J. P., & Mérette, C. (2006). Epidemiology of insomnia: Prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Medicine, 7, 123–130. CrossRefPubMed
3.
Stepanski, E., Koshorek, G., Zorick, F., Glinn, M., & Roehrs, T. (1989). Characteristics of individuals who do or do not seek treatment for chronic insomnia. Psychosomatics, 30(4), 421–427. doi: 10.​1016/​S0033-3182(89)72248-9.
4.
Roth, T., Coulouvrat, C., Hajak, G., Lakoma, M. D., Sampson, N. A., Shahly, V., et al. (2011). Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders, Second Edition Criteria: Results from the America Insomnia Survey. Biological Psychiatry, 69, 592–600. CrossRefPubMed
5.
Léger, D., Morin, C. M., Uchiyama, M., Hakimi, Z., Cure, S. S., & Walsh, J. K. (2012). Chronic insomnia, quality-of-life, and utility scores: Comparison with good sleepers in a cross-sectional international survey. Sleep Medicine, 13, 43–51. CrossRefPubMed
6.
Komada, Y., Nomura, T., Kusumi, M., Nakashima, K., Okajima, I., Sasai, T., et al. (2012). A two-year follow-up study on the symptoms of sleep disturbances/insomnia and their effects on daytime functioning. Sleep Medicine, 13, 1115–1121. CrossRefPubMed
7.
Sasai, T., Inoue, Y., Komada, Y., Nomura, T., Matsuura, M., & Matsushima, E. (2010). Effects of insomnia and sleep medication on health-related quality of life. Sleep Medicine, 11, 6. CrossRef
8.
Lee, M., Choh, A. C., Demerath, E. W., Knutson, K. L., Duren, D. L., Sherwood, R. J., et al. (2009). Sleep disturbance in relation to health-related quality of life in adults: The Fels Longitudinal Study. The Journal of Nutrition, Health and Aging, 13, 576–583. CrossRefPubMedCentralPubMed
9.
Bolge, S. C., Doan, J. F., Kannan, H., & Baran, R. W. (2009). Association of insomnia with quality of life, work productivity, and activity impairment. Quality of Life Research, 18, 415–422. CrossRefPubMed
10.
LeBlanc, M., Beaulieu-Bonneau, S., Mérette, C., Savard, J., & Ivers, H. (2007). Morin CM: Psychological and health-related quality of life factors associated with insomnia in a population-based sample. Journal of Psychosomatic Research, 63, 157–166. CrossRefPubMed
11.
Schubert, C. R., Cruickshanks, K. J., Dalton, D. S., Klein, B. E. K., Klein, R., & Nondahl, D. M. (2002). Prevalence of sleep problems and quality of life in an older population. Sleep, 25, 889–893. PubMed
12.
Katz, D. A., & McHorney, C. A. (2002). The relationship between insomnia and health-related quality of life in patients with chronic illness. Journal of Family Practice, 51, 229–235. PubMed
13.
Buysse, D. J., Ancoli-Israel, S., Edinger, J. D., Lichstein, K. L., & Morin, C. M. (2006). Recommendations for a standard research assessment of insomnia. Sleep, 29, 1155–1173. PubMed
14.
Krystal, A. D. (2007). Treating the health, quality of life, and functional impairments in insomnia. Journal of Clinical Sleep Medicine, 3, 63–72. PubMed
15.
Kyle, S. D., Morgan, K., & Espie, C. A. (2010). Insomnia and health-related quality of life. Sleep Medicine Reviews, 14, 69–82. CrossRefPubMed
16.
Ishak, W. W., Bagot, K., Thomas, S., Magakian, N., Bedwani, D., Larson, D., et al. (2012). Quality of life in patients suffering from insomnia. Innovations in Clinical Neuroscience, 9, 13–26. PubMedCentralPubMed
17.
Hajak, G., Rodenbeck, A., Voderholzer, U., Riemann, D., Cohrs, S., Hohagen, F., et al. (2001). Doxepin in the treatment of primary insomnia: A placebo-controlled, double-blind, polysomnographic study. Journal of Clinical Psychiatry, 62, 453–463. CrossRefPubMed
18.
Krystal, A. D., Walsh, J. K., Laska, E., Caron, J., Amato, D. A., Wessel, T. C., et al. (2003). Sustained efficacy of eszopiclone over 6 months of nightly treatment: Results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep, 26, 793–799. PubMed
19.
Asnis, G. M., Chakraburtty, A., DuBoff, E. A., Krystal, A. D., Londborg, P. D., Rosenberg, R., et al. (1999). Zolpidem for persistent insomnia in SSRI-treated depressed patients. Journal of Clinical Psychiatry, 60, 668–676. CrossRefPubMed
20.
Walsh, J. K., Roth, T., Randazzo, A., Erman, M., Jamieson, A., Scharf, M., et al. (2000). Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep, 23, 1087–1096. PubMed
21.
22.
Bertisch, S. M., Herzig, S. J., Winkelman, J. W., & Buettner, C. (2014). National use of prescription medications for insomnia: NHANES 1999–2010. Sleep, 37, 343–349. PubMedCentralPubMed
23.
Stahl, S. M. (2002). Selective actions on sleep or anxiety by exploiting GABA-A/benzodiazepine receptor subtypes. Journal of Clinical Psychiatry, 63, 179–180. CrossRefPubMed
24.
McCall, C., & McCall, W. V. (2012). What is the role of sedating antidepressants, antipsychotics, and anticonvulsants in the management of insomnia? Current Psychiatry Reports, 14, 494–502. CrossRefPubMed
25.
26.
27.
28.
Gandek, B. (1998). Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project. Journal of Clinical Epidemiology, 51, 903–912. CrossRefPubMed
29.
Ware, J. E., Jr., Kosinski, M., & Keller, S. D. (1996). A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Medical Care, 34, 220–233. CrossRefPubMed
30.
Léger, D., Scheuermaier, K., Paillard, M., & Guilleminault, C. (2001). SF-36: Evaluation of quality of life in severe and mild insomniacs compared with good sleepers. Psychosomatic Medicine, 63, 49–55. CrossRefPubMed
31.
Le Guen, Y., Gagnadoux, F., Hureaux, J., Jeanfaivre, T., Meslier, N., Racineux, J. L., & Urban, T. (2007). Sleep disturbances and impaired daytime functioning in outpatients with newly diagnosed lung cancer. Lung Cancer, 58(1), 139–143. doi: 10.​1016/​j.​lungcan.​2007.​05.​021.
32.
Vena, C. I., Parker, K. P., Allen, R., Bliwise, D. L., & Kimble, L. (2007). Sleep-wake disturbances and quality of life in patients with advanced lung cancer. Oncology Nursing Forum, 33, 761–769. CrossRef
33.
Tsilika, E., Gennatas, C., Galanos, A., & Vlahos, L. (2008). How is sleep quality affected by the psychological and symptom distress of advanced cancer patients? Palliative Medicine, 23, 46–53. CrossRefPubMed
34.
Cheak-Zamora, N. C., Wyrwich, K. W., & McBride, T. D. (2009). Reliability and validity of the SF-12v2 in the medical expenditure panel survey. Quality of Life Research, 18, 727–735. CrossRefPubMed
35.
36.
37.
D’Hoore, W., Bouckaert, A., & Tilquin, C. (1996). Practical considerations on the use of the Charlson comorbidity index with administrative data bases. Journal of Clinical Epidemiology, 49, 1429–1433. CrossRefPubMed
38.
39.
Bootzin, R. R., & Epstein, D. R. (2011). Understanding and treating insomnia. Annual Review of Clinical Psychology, 7, 435–458. CrossRefPubMed
40.
Meissner, H. H., Riemer, A., Santiago, S. M., Stein, M., Goldman, M. D., & Williams, A. J. (1998). Failure of physician documentation of sleep complaints in hospitalized patients. Western Journal of Medicine, 169, 146–149. PubMedCentralPubMed
41.
42.
Rosen, R. C., Zozula, R., Jahn, E. G., & Carson, J. L. (2001). Low rates of recognition of sleep disorders in primary care: Comparison of a community-based versus clinical academic setting. Journal of Chronic Diseases, 2, 47–55.
43.
Senthilvel, E., Auckley, D., & Dasarathy, J. (2011). Evaluation of sleep disorders in the primary care setting: History taking compared to questionnaires. Journal of Clinical Sleep Medicine, 7, 41–48. PubMedCentralPubMed
44.
Morlock, R. J., Tan, M., & Mitchell, D. Y. (2006). Patient characteristics and patterns of drug use for sleep complaints in the United States: Analysis of National Ambulatory Medical Survey data, 1997–2002. Clinical Therapeutics, 28, 1044–1053. CrossRefPubMed
45.
Lai, L. L., Tan, M. H., & Lai, Y. C. (2011). Prevalence and factors associated with off-label antidepressant prescriptions for insomnia. DHPS, 3, 27–36. CrossRef
46.
Roehrs, T., & Roth, T. (2004). “Hypnotic” prescription patterns in a large managed-care population. Sleep Medicine, 5, 463–466. CrossRefPubMed
47.
Pawaskar, M. D., Joish, V. N., Camacho, F. T., Rasu, R. S., & Balkrishnan, R. (2008). The influence of co-morbidities on prescribing pharmacotherapy for insomnia: Evidence from US national outpatient data 1995–2004. Journal of Medical Economics, 11, 41–56. CrossRefPubMed
48.
Ohayon, M. M. (2002). Epidemiology of insomnia: What we know and what we still need to learn. Sleep Medicine Reviews, 6, 15. CrossRef
49.
Ohayon, M. M., & Roth, T. (2001). What are the contributing factors for insomnia in the general population? Journal of Psychosomatic Research, 51, 745–755. CrossRefPubMed
50.
Swanson, L. M., Arnedt, J. T., Rosekind, M. R., Belenky, G., Balkin, T. J., & Drake, C. L. (2011). Sleep disorders and work performance: Findings from the 2008 National Sleep Foundation Sleep in America poll. Journal of Sleep Research, 20, 487–494. CrossRefPubMed
51.
Ozminkowski, R. J., Wang, S., & Walsh, J. K. (2007). The direct and indirect costs of untreated insomnia in adults in the United States. Sleep, 30, 263–273. PubMed
52.
53.
Rombaut, N., Maillard, F., & Kelly, F. (1990). The quality of life of insomniacs questionnaire (QOLI). Medical Science Research, 18, 845–847.
54.
Léger, D., Scheuermaier, K., Raffray, T., Metlaine, A., Choudat, D., & Guilleminault, C. (2005). HD-16: A new quality of life instrument specifically designed for insomnia. Sleep Medicine, 6, 191–198. CrossRefPubMed
55.
Kyle, S. D., Crawford, M. R., Morgan, K., Spiegelhalder, K., Clark, A. A., & Espie, C. A. (2013). The Glasgow Sleep Impact Index (GSII): A novel patient-centred measure for assessing sleep-related quality of life impairment in Insomnia Disorder. Sleep Medicine, 14, 493–501. CrossRefPubMed
56.
Morgan, K., Dixon, S., Mathers, N., Thompson, J., & Tomeny, M. (2003). Psychological treatment for insomnia in the management of long-term hypnotic drug use: A pragmatic randomised controlled trial. British Journal of General Practice, 53(497), 923–928.
57.
Espie, C. A., MacMahon, K. M. A., Kelly, H.-L., Broomfield, N. M., Douglas, N. J., Engleman, H. M., et al. (2007). Randomized clinical effectiveness trial of nurse-administered small-group cognitive behavior therapy for persistent insomnia in general practice. Sleep, 30, 574–584. PubMed
58.
Soeffing, J. P., Lichstein, K. L., Nau, S. D., McCrae, C. S., Wilson, N. M., Aguillard, R. N., et al. (2008). Psychological treatment of insomnia in hypnotic-dependant older adults. Sleep Medicine, 9, 165–171. CrossRefPubMedCentralPubMed
59.
Morin, C. M., Koetter, U., Bastien, C. H., Ware, J. C., & Wooten, V. (2005). Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep, 28, 1465–1471. PubMed
60.
McCall, W. V., Erman, M., Krystal, A. D., Rosenberg, R., Scharf, M. M., Zammit, G. K., et al. (2006). A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion, 22, 1633–1642. CrossRefPubMed
61.
Wagner, J., & Wagner, M. (2000). Non-benzodiazepines for the treatment of insomnia. Sleep Medicine Reviews, 4, 31. CrossRef
62.
63.
64.
65.
66.
Roehrs, T., & Roth, T. (2010). Drug-related sleep stage changes: Functional significance and clinical relevance. Sleep Medicine Clinics, 5, 559–570. CrossRefPubMedCentralPubMed
67.
Tobler, I., Kopp, C., Deboer, T., & Rudolph, U. (2001). Diazepam-induced changes in sleep: Role of the alpha 1 GABA(A) receptor subtype. Proceedings of the National Academic Science Unite States of America, 98, 6464–6469. CrossRef
68.
Zisapel, N. (2007). Sleep and sleep disturbances: Biological basis and clinical implications. Cellular and Molecular Life Sciences, 64, 1174–1186. CrossRefPubMed
69.
Johnson, A. E., & Sanchez, M. E. (1993). Household and medical provider reports on medical conditions: National medical expenditure survey, 1987. Journal of Economic and Social Measurement, 19, 199–223.
70.
Zuvekas, S. H., & Olin, G. L. (2009) Validating household reports of health care use in the medical expenditure panel survey. Health Services Research, 44(5p1), 1679–1700.
Metagegevens
Titel
Insomnia, hypnotic use, and health-related quality of life in a nationally representative sample
Auteurs
Julieta Scalo
Pooja Desai
Karen Rascati
Publicatiedatum
01-05-2015
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 5/2015
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-014-0842-1

Andere artikelen Uitgave 5/2015

Quality of Life Research 5/2015 Naar de uitgave

Brief Communication

Cultural adaptation and psychometric assessment of Pain Catastrophizing Scale among young healthy Malay-speaking adults in military settings

OriginalPaper

Validation of the Care-Related Quality of Life Instrument in different study settings: findings from The Older Persons and Informal Caregivers Survey Minimum DataSet (TOPICS-MDS)

Review

Evaluation of cross-cultural adaptation and measurement properties of breast cancer-specific quality-of-life questionnaires: a systematic review

Patient Engagement Special Section

Low-income minority patient engagement with automated telephonic depression assessment and impact on health outcomes

Patient Engagement Special Section

Engaging patients to recover life projectuality: an Italian cross-disease framework

Patient Engagement Special Section

Patient and public engagement in health-related quality of life and patient-reported outcomes research: what is important and why should we care? Findings from the first ISOQOL patient engagement symposium